Pfizer predicts modest 2026 guidance due to declining Covid product sales and older drug declines. Recent acquisitions like Metsera and Seagen have yet to pay off, impacting stock prices. Revenue for 2026 is forecasted at $59.5-$62.5 billion, a slight decrease from 2025. The company faces patent expirations and pricing pressures.

Sales of Covid vaccine and antiviral Paxlovid are expected to drop by $1.5 billion in 2026. Pfizer also anticipates a $1.5 billion decrease in sales due to expiring market exclusivity. Analysts believe the outlook reflects costs from recent acquisitions and restructuring efforts, with ongoing cost-cutting measures in place.

Pfizer exceeded its 2025 cost-saving goals and aims for $7 billion in cost cuts by 2027. The company faces uncertainty in U.S. vaccine policy changes under Health and Human Services Secretary Robert F. Kennedy Jr. CEO Bourla dismisses FDA remarks, affirming commitment to vaccines. Pricing deals with the Trump administration will lead to price and margin compression.

Read more at CNBC

1. Apple announces plans to invest $430 billion in the US over the next five years, creating 20,000 new jobs.
2. GameStop stock surges 27% as Reddit traders rally behind the meme stock.
3. Pfizer reports $7.8 billion in revenue from its Covid-19 vaccine in the first quarter of 2021.
4. Tesla’s quarterly revenue jumps by 74% to $10.39 billion, beating expectations.
5. Amazon posts record-breaking $108.5 billion in revenue for the first quarter of 2021.: Pfizer 2026 guidance shows Metsera, Seagen deals will take time to pay off